A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer

Institut Jules Bordet, Brussels

Orszagos Onkologiai Intezet Kemoterapia B es Klin.Farm.Oszt., Budapest

Cliniques Universitaires St. Luc Oncology - Breast Clinic, Brussels

Westmead Hospital, Westmead

UZ Leuven Campus Gasthuisberg Dept. of General Medical, Leuven

Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum Onkologiai Intezet, Debrecen

Clinique Sainte-Elisabeth Médecine Interne - Oncologie, Namur

Grand Hôpital de Charleroi Oncologie-Hématologie, Charleroi

Istituto Europeo di Oncologia, Milan

Istituto Europeo di Oncologia Divisione Sviluppo Nuovi Farmaci per Terapie Innovative, Milan

MD Anderson Cancer Center Unidad de Investigación Clínica, Madrid

H. Ramón y Cajal Servicio de Oncología Médica, Madrid

Institut Claudius Regaud Dpt d'Oncologie Médicale, Toulouse

Kliniken Essen-Mitte Klinik für Senologie - Brustzentrum, Essen

H. Clínico de Valencia Servicio de Hematología y oncología Médica, Valencia

KLINIKUM OFFENBACH Klinik für Gynäkologie und Geburtshilfe, Offenbach

Klinikum Offenbach, Offenbach

Institut Gustave Roussy Dépt d'oncologie - Cancer du sein, Villejuif

Institut Gustave Roussy, Villejuif

Peter MacCallum Cancer Centre, East Melbourne

McGill University Department of Oncologie - Clinical Reserach Program, Montreal

Princess Margaret Cancer Centre, Toronto

University Health Network - Princess Margaret Hospital, Toronto

H. Valle de Hebrón Servicio de Oncología, Barcelona

Hospital Universitario Val d'Hebròn, Madrid

Western General Hospital Edinburgh Cancer Centre, Edinburgh

Royal Marsden Hospital, London

The Royal Marsden NHS Trust Dpt of Medicine-Oncology, London

Nottingham University Hospitals NHS Trust Department of Clinical Oncology, Nottingham